The article discusses concerns over the growing ties between telehealth providers and pharmaceutical companies, particularly regarding discounted telehealth visits that may lead to increased prescriptions of expensive branded drugs. Experts warn that these partnerships could violate anti-kickback laws and promote unnecessary medication use.
The article highlights a growing concern over the intertwining of telehealth services and pharmaceutical companies, where discounted telehealth visits are used to drive prescriptions for specific drugs, potentially violating anti-kickback laws. For professionals in healthtech and biotech, this underscores the importance of scrutinizing partnerships and business models in digital health to ensure compliance with regulations and ethical standards, while evaluating opportunities for innovation that prioritize patient care and safety.